Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer

被引：13

作者：

Liu, Yanan ^{[1
,2
]}

Wang, Canwei ^{[1
]}

Li, Jifa ^{[1
]}

Zhu, Jiandong ^{[1
]}

Zhao, Chengguang ^{[1
,2
]}

Xu, Huanhai ^{[1
]}

机构：

[1] Wenzhou Med Univ, Affiliated Yueqing Hosp, Wenzhou, Peoples R China

[2] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2021年 / 12卷

关键词：

FGFR4; FGF19; cancer; activator; inhibitor;

D O I：

10.3389/fphar.2021.633453

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Fibroblast growth factor receptor 4 (FGFR4) is a tyrosine kinase receptor that is a member of the fibroblast growth factor receptor family and is stimulated by highly regulated ligand binding. Excessive expression of the receptor and its ligand, especially FGF19, occurs in many types of cancer. Abnormal FGFR4 production explains these cancer formations, and therefore, this receptor has emerged as a potential target for inhibiting cancer development. This review discusses the diverse mechanisms of oncogenic activation of FGFR4 and highlights some currently available inhibitors targeting FGFR4.

引用

页数：10

共 87 条

[81] p38-regulated FOXC1 stability is required for colorectal cancer metastasis [J].

Zhang, Yi ;

Liao, Yan ;

Chen, Chaoyi ;

Sun, Wenjie ;

Sun, Xiaohui ;

Liu, Yuan ;

Xu, Enping ;

Lai, Maode ;

Zhang, Honghe .

JOURNAL OF PATHOLOGY, 2020, 250 (02) :217-230

[82] Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells [J].

Zhao, Chengguang ;

Yang, Lehe ;

Zhou, Feng ;

Yu, Yun ;

Du, Xiaojing ;

Xiang, Youqun ;

Li, Chenglong ;

Huang, Xiaoying ;

Xie, Congying ;

Liu, Zhiguo ;

Lin, Jiayuh ;

Wang, Liangxing ;

Liang, Guang ;

Cui, Ri .

ONCOGENE, 2020, 39 (20) :3997-4013

[83] Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism [J].

Zhao, Chengguang ;

Li, Huameng ;

Lin, Huey-Jen ;

Yang, Shulin ;

Lin, Jiayuh ;

Liang, Guang .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (01) :47-61

[84] FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β-catenin signaling cascade via FGFR4 activation [J].

Zhao, Huakan ;

Lv, Fenglin ;

Liang, Guizhao ;

Huang, Xiaobin ;

Wu, Gang ;

Zhang, Wenfa ;

Yu, Le ;

Shi, Lei ;

Teng, Yong .

ONCOTARGET, 2016, 7 (12) :13575-13586

[85] FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression [J].

Zhao, Xiangdong ;

Xu, Faliang ;

Dominguez, Nestor P. ;

Xiong, Yuanping ;

Xiong, Zhongxun ;

Peng, Hong ;

Shay, Chloe ;

Teng, Yong .

MOLECULAR CARCINOGENESIS, 2018, 57 (11) :1616-1625

[86] Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling [J].

Zheng, Hailun ;

Yang, Lehe ;

Kang, Yanting ;

Chen, Min ;

Lin, Shichong ;

Xiang, Youqun ;

Li, Caleb ;

Dai, Xuanxuan ;

Huang, Xiaoying ;

Liang, Guang ;

Zhao, Chengguang .

MOLECULAR CARCINOGENESIS, 2019, 58 (04) :565-576

[87] A Structure-Guided Approach to Creating Covalent FGFR Inhibitors [J].

Zhou, Wenjun ;

Hur, Wooyoung ;

McDermott, Ultan ;

Dutt, Amit ;

Xian, Wa ;

Ficarro, Scott B. ;

Zhang, Jianming ;

Sharma, Sreenath V. ;

Brugge, Joan ;

Meyerson, Matthew ;

Settleman, Jeffrey ;

Gray, Nathanael S. .

CHEMISTRY & BIOLOGY, 2010, 17 (03) :285-295

← 1 2 3 4 5 6 7 8 9 →